Aesthetic manufacturer Sinclair has released a new study demonstrating the safety of
dermal filler MaiLi. The company explains that the research is based on an observation period from February 2021 to April 2023, during which time there was one adverse event in every 3,698 syringes delivered, resulting in an overall adverse incidence of 0.027%.
In the study, adverse events were counted as bleeding, ecchymosis, erythema, haematoma, skin redness, bruising, swelling, oedema, infection, local pain and/or itching, sensitivity, hardness, lumps/ nodule or injection-site discolouration.
Lauren Clarke, Sinclair’s head of marketing UK and Ireland, commented, “MaiLi’s OxiFree technology offers next-generation fillers that are not only tailored to meet differing needs – from fine lines to facial volumising – but also help clinics to achieve natural, long-lasting results with minimal adverse events. Confidence in this type of HA filler is essential for both practitioners and their patients.
At Sinclair, we take the safety and efficacy of our products very seriously, and believe that evidence-based surveillance findings are essential for helping to build that confidence.”
The paper is titled A Preliminary Report on the Safety and Efficacy of a Novel MaiLi HA Filler for Facial Correction of Wrinkles, Folds, Volume and Lips, and was compiled by researchers Dr Patrick Micheels and Mickaël Poiraud.
